0001209191-21-059986.txt : 20211007 0001209191-21-059986.hdr.sgml : 20211007 20211007190312 ACCESSION NUMBER: 0001209191-21-059986 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210927 FILED AS OF DATE: 20211007 DATE AS OF CHANGE: 20211007 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moran Michael Shawn CENTRAL INDEX KEY: 0001886788 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36306 FILM NUMBER: 211313432 MAIL ADDRESS: STREET 1: C/O EAGLE PHARMACEUTICALS, INC. STREET 2: 50 TICE BLVD., SUITE 315 CITY: WOODCLIFF STATE: NJ ZIP: 07677 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EAGLE PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000827871 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-326-5300 MAIL ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: EAGLE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19880120 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-09-27 0 0000827871 EAGLE PHARMACEUTICALS, INC. EGRX 0001886788 Moran Michael Shawn C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315 WOODCLIFF LAKE NJ 07677 0 1 0 0 EVP, Chief Commercial Officer Common Stock 24268 D Employee Stock Option (right to buy) 66.32 2026-01-27 Common Stock 10000 D Employee Stock Option (right to buy) 84.92 2027-01-03 Common Stock 27000 D Employee Stock Option (right to buy) 59.14 2028-01-06 Common Stock 5000 D Employee Stock Option (right to buy) 41.37 2029-01-29 Common Stock 1594 D Employee Stock Option (right to buy) 59.79 2030-01-05 Common Stock 37500 D 20,828 of the shares represent restricted stock units ("RSU") awards. The RSUs shall vest: 253 RSUs on January 7, 2022; 563 RSUs on January 29, 2022; 562 RSUs on January 29, 2023; 3,750 RSUs on each of January 5, 2022, January 5, 2023 and January 5, 2024; and 2,050 RSUs on each of February 2, 2022, February 2, 2023, February 2, 2024 and February 2, 2025, subject to the Reporting Person's continuous service through each vesting date. The options are fully vested and exercisable. One fourth (1/4th) of the shares underlying the option vested on January 7, 2019, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date. The option grant was initially 4,500 shares of which one fourth (1/4th) of the shares underlying the option vested on January 29, 2020, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date. One fourth (1/4th) of the shares underlying the option vested on January 5, 2021, the remaining shares underlying the option shall vest one thirty-sixth (1/36th) monthly thereafter, subject to the Reporting Person's continuous service through each vesting date. /s/ Brian Cahill, Attorney-in-Fact 2021-10-07 EX-24.3_1012290 2 poa.txt POA DOCUMENT Exhibit 24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Brian Cahill and Ryan Debski of Eagle Pharmaceuticals, Inc. (the "Company") and each of Marc Recht (attorney), Paul Alexander (attorney), Jonathan Robertson (attorney), Julie Allison Weltman (attorney), and Jason Minio (senior paralegal) of the law firm Cooley LLP ("Cooley"), signing individually, the undersigned's true and lawful attorney-in fact and agent to: (1) prepare, execute on behalf of the undersigned, and submit to the U.S. Securities and Exchange Commission (the "SEC") any documents necessary or advisable to obtain EDGAR access codes or make any updates to the undersigned's EDGAR access codes once obtained, enabling the undersigned to make electronic filings of reports with the SEC; (2) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder; (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the SEC and any stock exchange or similar authority; and (4) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact shall no longer be employed by the Company or by Cooley, as applicable. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of October 2021. /s/ Michael Moran Michael Moran